Marker Therapeutics, Inc. (MRKR) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

ImmunoPrecise Antibodies Ltd.

ImmuCell Corp.

Marker Therapeutics, Inc.

HOOKIPA Pharma, Inc.

Solid Biosciences, Inc.

Cognition Therapeutics, Inc.

VistaGen Therapeutics, Inc.

Gain Therapeutics, Inc.

Mainz Biomed NV

Viracta Therapeutics, Inc.

CytoMed Therapeutics Ltd.

Why is Marker Therapeutics, Inc. ?

The company has declared negative results in Mar'2025 after 12 consecutive positive quarters

NET SALES(HY) At USD 1.21 MM has Grown at -49.85%
ROCE(HY) Lowest at -144.68%
OPERATING PROFIT(Q) Lowest at USD -4.26 MM

Risky - Negative EBITDA

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of -66.97%, its profits have fallen by -9%

Consistent Underperformance against the benchmark over the last 3 years

Along with generating -66.97% returns in the last 1 year, the stock has also underperformed S&P 500 in each of the last 3 annual periods

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Marker Therapeutics, Inc. for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

Marker Therapeutics, Inc.

-58.72%

-0.64

107.13%

S&P 500

13.22%

0.61

20.17%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

41.69%

EBIT Growth (5y)

6.79%

EBIT to Interest (avg)

-24.11

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.94

Sales to Capital Employed (avg)

0.51

Tax Ratio

0.39%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

40.37%

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

1.38

EV to EBIT

-0.50

EV to EBITDA

-0.50

EV to Capital Employed

6.33

EV to Sales

1.11

PEG Ratio

Dividend Yield

ROCE (Latest)

-1272.49%

ROE (Latest)

-85.09%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

No Signal

Bollinger Bands

Sideways

Mildly Bearish

Moving Averages

Mildly Bearish (Daily)

KST

Mildly Bullish

Bearish

Dow Theory

No Trend

Mildly Bullish

OBV

No Trend

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

7What is working for the Company

OPERATING CASH FLOW(Y)

Highest at USD -10.88 MM

NET PROFIT(HY)

Higher at USD -8.01 MM

RAW MATERIAL COST(Y)

Fallen by 0% (YoY

DEBT-EQUITY RATIO (HY)

Lowest at -112.63 %

-23What is not working for the Company

NET SALES(HY)

At USD 1.21 MM has Grown at -49.85%

ROCE(HY)

Lowest at -144.68%

OPERATING PROFIT(Q)

Lowest at USD -4.26 MM

PRE-TAX PROFIT(Q)

Lowest at USD -4.02 MM

NET PROFIT(Q)

Lowest at USD -4.02 MM

Here's what is working for Marker Therapeutics, Inc.

Operating Cash Flow

Highest at USD -10.88 MM and Grown

In each year in the last three years

MOJO Watch

The company has generated higher cash revenues from business operations

Operating Cash Flows (USD MM)

Debt-Equity Ratio

Lowest at -112.63 %

in the last five Semi-Annual periods

MOJO Watch

The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Raw Material Cost

Fallen by 0% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Marker Therapeutics, Inc.

Net Sales

At USD 1.21 MM has Grown at -49.85%

Year on Year (YoY)

MOJO Watch

Near term sales trend is very negative

Net Sales (USD MM)

Operating Profit

Lowest at USD -4.26 MM and Fallen

In each period in the last five periods

MOJO Watch

Near term Operating Profit trend is quite negative

Operating Profit (USD MM)

Pre-Tax Profit

Lowest at USD -4.02 MM and Fallen

In each period in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (USD MM)

Pre-Tax Profit

At USD -4.02 MM has Fallen at -30.78%

over average net sales of the previous four periods of USD -3.07 MM

MOJO Watch

Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (USD MM)

Net Profit

At USD -4.02 MM has Fallen at -30.25%

over average net sales of the previous four periods of USD -3.08 MM

MOJO Watch

Near term Net Profit trend is very negative

Net Profit (USD MM)

Net Profit

Lowest at USD -4.02 MM

in the last five periods

MOJO Watch

Near term Net Profit trend is negative

Net Profit (USD MM)